ストックスクリーナーアプリを入手
25.12
0.84%
0.21
アフターアワーズ：
25.12
前日終値:
$24.91
開ける：
$23
24時間の取引高:
2.24M
Relative Volume:
2.61
時価総額：
$1.22B
収益：
$681.75M
当期純損益:
$70.47M
株価収益率:
17.32
EPS:
1.45
ネットキャッシュフロー:
$173.19M
1週間 パフォーマンス:
-5.03%
1か月 パフォーマンス:
-2.79%
6か月 パフォーマンス:
+45.71%
1年 パフォーマンス:
-15.87%
1日の値動き範囲:
$23.00
$25.80
1週間の範囲:
$23.00
$26.44
52週間の値動き範囲:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
名前
Pacira Biosciences Inc
セクター
電話
813-553-6680
住所
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
PCRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.12 | 1.22B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | アップグレード | Truist | Sell → Hold |
| 2024-08-13 | ダウングレード | Truist | Buy → Sell |
| 2024-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2024-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 再開されました | JP Morgan | Overweight |
| 2023-12-20 | 開始されました | Raymond James | Outperform |
| 2023-08-03 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 再開されました | Wedbush | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-01-03 | 再開されました | JP Morgan | Overweight |
| 2021-07-26 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 再開されました | JP Morgan | Neutral |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Neutral |
| 2020-04-07 | 開始されました | Northland Capital | Outperform |
| 2020-03-20 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 開始されました | SunTrust | Buy |
| 2020-01-23 | 開始されました | SunTrust | Buy |
| 2019-11-06 | 開始されました | BTIG Research | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-06 | アップグレード | Mizuho | Underperform → Neutral |
| 2019-05-02 | アップグレード | Stifel | Sell → Hold |
| 2019-02-01 | ダウングレード | Mizuho | Neutral → Underperform |
| 2018-08-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-21 | 繰り返されました | Mizuho | Neutral |
| 2018-02-16 | ダウングレード | Needham | Buy → Hold |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2018-01-04 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Mkt Perform |
すべてを表示
Pacira Biosciences Inc (PCRX) 最新ニュース
Earnings call transcript: Pacira Q1 2025 shows revenue miss, stock dips - Investing.com Australia
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Target Lowered | PCRX Stock News - GuruFocus
Where Pacira BioSciences Stands With Analysts - Benzinga
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady - marketscreener.com
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... - Yahoo
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences Reports Q1 2025 Financial Results - TipRanks
Pacer Advisors, Inc. Significantly Reduces Holdings in Pacira BioSciences Inc - GuruFocus
Pacer Advisors, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
Pacira BioSciences Inc Q1 2025 Earnings: EPS of $0.10 Misses Estimate, Revenue at $168.9 Million Below Forecast - GuruFocus
PCRX Reports Lower-Than-Expected Q1 Revenue, Focuses on Long-Term Strategy | PCRX Stock News - GuruFocus
Earnings Flash (PCRX) Pacira BioSciences Reports Q1 Adjusted EPS $0.62, vs. FactSet Est of $0.60 - marketscreener.com
Earnings Flash (PCRX) Pacira BioSciences Posts Q1 Revenue $168.9M, vs. FactSet Est of $176.0M - marketscreener.com
Pacira BioSciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Closing Strong: Pacira BioSciences Inc (PCRX) Ends at 25.15, Down -2.56 from Last Close - DWinneX
Preview: Pacira BioSciences's Earnings - Nasdaq
Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Pacira (PCRX) Reveals Promising Phase 1 Study Data for Gene Ther - GuruFocus
Pacira BioSciences to Present 3-Year Safety and Efficacy - GlobeNewswire
Revolutionary Gene Therapy Shows 3-Year Results for Knee Osteoarthritis: Pacira's PCRX-201 Data Revealed - Stock Titan
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - Louisiana First News
Pacira BioSciences soars 52% following InvestingPro’s October Fair Value alert By Investing.com - Investing.com
(PCRX) Trading Advice - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
How did Pacira BioSciences Inc (PCRX) fare last session? - uspostnews.com
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results - GuruFocus
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results | PCRX Stock News - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicit - GuruFocus
Pacira BioSciences to Present Findings on PCRX-201 Gene Therapy for Knee Osteoarthritis at ASGCT 2025 - Nasdaq
Pacira BioSciences to Present New Data on Clinical - GlobeNewswire
Revolutionary Gene Therapy Data: Pacira's New Approach Could Transform Knee Osteoarthritis Treatment - Stock Titan
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67 - Defense World
Are Smart Investors Making the Right Decision? Pacira BioSciences Inc (PCRX) - Sete News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
The Potential Rise in the Price of Pacira BioSciences Inc (PCRX) following insiders activity - knoxdaily.com
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for - Nasdaq
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - GlobeNewswire
Leading Pain Management Company Pacira Sets Q1 2025 Earnings Call DateKey Details Inside - Stock Titan
LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences Inc (PCRX) Shares Up 3.97% on Apr 28 - GuruFocus
Pacira releases positive two-year data on knee osteoarthritis candidate - Seeking Alpha
Pacira BioSciences' Gene Therapy Shows Long-Term Improvement in Knee Osteoarthritis Symptoms - marketscreener.com
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee - GlobeNewswire
Invesco Ltd. Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Pessimistic Outlook for PCRX Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Pacira BioSciences Inc (NASDAQ:PCRX)’s 12-Month Price Target Currently Stands At 48 - Marketing Sentinel
Do investors need to be concerned about Pacira BioSciences Inc (PCRX)? - uspostnews.com
Pacira Biosciences Inc (PCRX) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
1.62%
大文字化:
|
ボリューム (24 時間):